- Report
- August 2021
Europe
From €3264EUR$3,420USD£2,735GBP
- Drug Pipelines
- November 2020
- 114 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- April 2022
- 64 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- August 2024
- 95 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- May 2022
- 102 Pages
Global
From €1909EUR$2,000USD£1,599GBP
Ataxia is a neurological disorder that affects the coordination of movement. Ataxia drugs are used to treat the symptoms of this disorder, which can include difficulty walking, speaking, and swallowing. These drugs are part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological and psychiatric disorders. Ataxia drugs are typically prescribed to improve coordination and balance, as well as to reduce the risk of falls.
Ataxia drugs are typically divided into two categories: symptomatic and disease-modifying. Symptomatic drugs are used to reduce the symptoms of ataxia, while disease-modifying drugs are used to slow the progression of the disorder. Common symptomatic drugs include benzodiazepines, anticholinergics, and anticonvulsants. Disease-modifying drugs include immunomodulators, gene therapy, and stem cell therapy.
Some companies in the Ataxia Drug market include AbbVie, Biogen, Merck, Novartis, and Pfizer. Show Less Read more